Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Direskeneli

Showing results (11-20 of 98) with videos related to

Pageof 10
Sort By:
Annals of the Rheumatic Diseases|August 16, 2005
A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelinesM Temel, P Atagündüz, H Direskeneli
Scandinavian Journal of Rheumatology|May 21, 2005
Effects of interferon-alpha treatment on serum IL-6, IL-8, TNF-alpha and soluble TNF-alpha receptors in Behçet's diseaseH Direskeneli, I Fresko, V Hamuryudan
The Journal of Rheumatology|May 6, 1999
Levels of serum transforming growth factor-beta1 do not increase in Behçet's disease, in contrast to rheumatoid arthritisE Eksioglu-Demiralp, H Direskeneli, T Akoglu
The Journal of Rheumatology|April 12, 2001
Ninth International Conference on Behçet's Disease, Seoul, Korea, May 27-29, 2000M Schirmer, K T Calamia, H Direskeneli
Rheumatology (Oxford, England)|March 21, 2001
Anticardiolipin antibodies in Behçet's disease: a reassessmentS Tokay, H Direskeneli, S Yurdakul, et al.
Clinical and Experimental Rheumatology|November 14, 2007
The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's diseaseG Mumcu, N Inanc, S Yavuz, et al.
International Journal of Cardiac Imaging|February 24, 2001
Cardiac thrombosis in a patient with Behçet's disease: two years follow-upY Basaran, M Degertekin, H Direskeneli, et al.
Clinical and Experimental Rheumatology|November 2, 2004
T and NK cell subset changes with microbial extracts and human HSP60-derived peptides in Behçet's diseaseA Kibaroglu, E Eksioglu-Demiralp, T Akoglu, et al.
Clinical and Experimental Rheumatology|October 10, 2002
The effects of nitric oxide donors and inhibitors on neutrophil functions in Behçet's diseaseG Atalay, E Eksioglu-Demiralp, T Akoglu, et al.
Lupus|July 16, 2008
CD8+CD28-, suppressive T cells in systemic lupus erythematosusA Tulunay, S Yavuz, H Direskeneli, et al.
Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
Annals of the Rheumatic Diseases|August 16, 2005
A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelinesM Temel, P Atagündüz, H Direskeneli
Scandinavian Journal of Rheumatology|May 21, 2005
Effects of interferon-alpha treatment on serum IL-6, IL-8, TNF-alpha and soluble TNF-alpha receptors in Behçet's diseaseH Direskeneli, I Fresko, V Hamuryudan
The Journal of Rheumatology|May 6, 1999
Levels of serum transforming growth factor-beta1 do not increase in Behçet's disease, in contrast to rheumatoid arthritisE Eksioglu-Demiralp, H Direskeneli, T Akoglu
The Journal of Rheumatology|April 12, 2001
Ninth International Conference on Behçet's Disease, Seoul, Korea, May 27-29, 2000M Schirmer, K T Calamia, H Direskeneli
Rheumatology (Oxford, England)|March 21, 2001
Anticardiolipin antibodies in Behçet's disease: a reassessmentS Tokay, H Direskeneli, S Yurdakul, et al.
Clinical and Experimental Rheumatology|November 14, 2007
The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's diseaseG Mumcu, N Inanc, S Yavuz, et al.
International Journal of Cardiac Imaging|February 24, 2001
Cardiac thrombosis in a patient with Behçet's disease: two years follow-upY Basaran, M Degertekin, H Direskeneli, et al.
Clinical and Experimental Rheumatology|November 2, 2004
T and NK cell subset changes with microbial extracts and human HSP60-derived peptides in Behçet's diseaseA Kibaroglu, E Eksioglu-Demiralp, T Akoglu, et al.
Clinical and Experimental Rheumatology|October 10, 2002
The effects of nitric oxide donors and inhibitors on neutrophil functions in Behçet's diseaseG Atalay, E Eksioglu-Demiralp, T Akoglu, et al.
Lupus|July 16, 2008
CD8+CD28-, suppressive T cells in systemic lupus erythematosusA Tulunay, S Yavuz, H Direskeneli, et al.
Pageof 10